Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) announced its participation in the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. The company will present a corporate update on March 18, 2021, at 9:20 a.m. EDT, focusing on the clinical progress of CUE-101, its lead therapeutic for HPV+ recurrent/metastatic head and neck cancer. Additionally, they will discuss advancements in the CUE-400 series, targeting various autoimmune diseases. The presentation will be available via webcast and archived for 30 days on their website.

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021.

Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, the lead Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The presentation will also focus on the Company’s platform developments and pipeline progress including the CUE-400 series, a novel class of therapeutic molecules for broad applications in multiple autoimmune diseases.

Presentation Details
Oppenheimer 31st Annual Healthcare Conference
Date and Time:	Thursday, March 18, 2021 at 9:20 a.m. EDT
Webcast link:	https://wsw.com/webcast/oppenheimer9/cue/2481281

A live and archived webcast of the presentation will be available in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor Contact
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com

Media Contact
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com

 

FAQ

When will Cue Biopharma present at the Oppenheimer 31st Annual Healthcare Conference?

Cue Biopharma will present on March 18, 2021, at 9:20 a.m. EDT.

What is the focus of Cue Biopharma's presentation at the conference?

The focus will be on the clinical progress of CUE-101 for HPV+ recurrent/metastatic head and neck cancer and advancements in the CUE-400 series.

Where can I watch Cue Biopharma's presentation at the Oppenheimer conference?

The presentation can be watched via a webcast available on Cue Biopharma's website.

Is Cue Biopharma participating in any clinical trials?

Yes, Cue Biopharma is conducting clinical trials for CUE-101 targeting HPV+ head and neck cancer.

What therapeutic areas does Cue Biopharma focus on?

Cue Biopharma focuses on cancer, infectious diseases, and autoimmune diseases.